BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 21039887)

  • 1. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
    Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe use of livers from donors with positive hepatitis B core antibody.
    Manzarbeitia C; Reich DJ; Ortiz JA; Rothstein KD; Araya VR; Munoz SJ
    Liver Transpl; 2002 Jun; 8(6):556-61. PubMed ID: 12037788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.
    Ghisetti V; Marzano A; Zamboni F; Barbui A; Franchello A; Gaia S; Marchiaro G; Salizzoni M; Rizzetto M
    Liver Transpl; 2004 Mar; 10(3):356-62. PubMed ID: 15004761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report.
    Lu SC; Yan LN; Li B; Ma YK; Liu C; Wen TF; Lin QY; Zhao JC; Wang XB; Li XD; Qing S; Zhao LS; Liu C; Liu J; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):196-201. PubMed ID: 14599968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors.
    Chang MS; Olsen SK; Pichardo EM; Heese S; Stiles JB; Abdelmessih R; Verna EC; Guarrera JV; Emond JC; Brown RS
    Liver Transpl; 2012 Jul; 18(7):834-8. PubMed ID: 22422699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience.
    Bohorquez HE; Cohen AJ; Girgrah N; Bruce DS; Carmody IC; Joshi S; Reichman TW; Therapondos G; Mason AL; Loss GE
    Liver Transpl; 2013 Jun; 19(6):611-8. PubMed ID: 23526668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis.
    Skagen CL; Jou JH; Said A
    Clin Transplant; 2011; 25(3):E243-9. PubMed ID: 21323735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.